APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Retinal Degenerative Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Retinal Degenerative Disease Treatment Market Outlook and Growth Opportunities 2026

Report ID 17444347054 July 2026214 pages

Choose your research edition.

Industry ResearchRetinal Degenerative Disease Treatment Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Retinal Degenerative Disease Treatment Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Retinal Degenerative Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Retinal Degenerative Disease Treatment Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Retinal Degenerative Disease Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Retinal Degenerative Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Retinal Degenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Retinal Degenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Retinal Degenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Retinal Degenerative Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Retinal Degenerative Disease Treatment market include Sucampo Pharmaceuticals, Vivani Medical(Second Sight Medical), Roche, ReNeuron, ReGenX Biosciences, Regeneron Pharmaceuticals, Orphagen Pharmaceuticals, Inc., Okuvision and Ocugen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Retinal Degenerative Disease Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Retinal Degenerative Disease Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Retinal Degenerative Disease Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Retinal Degenerative Disease Treatment market.

Retinal Degenerative Disease Treatment Segment by Company

Sucampo Pharmaceuticals

Vivani Medical(Second Sight Medical)

Roche

ReNeuron

ReGenX Biosciences

Regeneron Pharmaceuticals

Orphagen Pharmaceuticals, Inc.

Okuvision

Ocugen

Novartis

Nano Retina

M's Science Corporation

Mimetogen Pharmaceuticals Inc.

Kanghong Pharma

Ionis Pharmaceuticals, Inc.

International Stem Cell Corporation

InFlectis BioScience

Grupo Ferrer Internacional, S.A.

GenSight Biologics S.A.

Genethon

Genable Technologies Limited

Dompe Farmaceutici S.p.A.

Caladrius Biosciences, Inc.

Bayer HealthCare

Astellas Pharma Inc.

Amarantus BioScience

Retinal Degenerative Disease Treatment Segment by Type

Age Related Macular Degeneration (AMD) Treatment

Retinitis Pigmentosa (RP) Treatment

Retinal Degenerative Disease Treatment Segment by Application

20 to 60 Years Old

60 and Over

Others

Retinal Degenerative Disease Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Retinal Degenerative Disease Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Retinal Degenerative Disease Treatment key companies, revenue, market share, and recent developments.

3. To split the Retinal Degenerative Disease Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Retinal Degenerative Disease Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Retinal Degenerative Disease Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Retinal Degenerative Disease Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Degenerative Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Retinal Degenerative Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Degenerative Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Retinal Degenerative Disease Treatment industry.

Chapter 3: Detailed analysis of Retinal Degenerative Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Retinal Degenerative Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Retinal Degenerative Disease Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Retinal Degenerative Disease Treatment Industry Trends Table 2. Retinal Degenerative Disease Treatment Industry Drivers Table 3. Retinal Degenerative Disease Treatment Industry Opportunities and Challenges Table 4. Retinal Degenerative Disease Treatment Industry Restraints Table 5. Global Retinal Degenerative Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Retinal Degenerative Disease Treatment Revenue Share by Company (2021-2026) Table 7. Global Retinal Degenerative Disease Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Retinal Degenerative Disease Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Retinal Degenerative Disease Treatment Company, Product Type & Application Table 10. Global Retinal Degenerative Disease Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Retinal Degenerative Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Age Related Macular Degeneration (AMD) Treatment Table 15. Significant Companies of Retinitis Pigmentosa (RP) Treatment Table 16. Global Retinal Degenerative Disease Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Retinal Degenerative Disease Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Retinal Degenerative Disease Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Retinal Degenerative Disease Treatment Sales Value Share by Type (2021-2026) Table 20. Global Retinal Degenerative Disease Treatment Sales Value Share by Type (2027-2032) Table 21. Significant Companies of 20 to 60 Years Old Table 22. Significant Companies of 60 and Over Table 23. Significant Companies of Others Table 24. Global Retinal Degenerative Disease Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Retinal Degenerative Disease Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Retinal Degenerative Disease Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Retinal Degenerative Disease Treatment Sales Value Share by Application (2021-2026) Table 28. Global Retinal Degenerative Disease Treatment Sales Value Share by Application (2027-2032) Table 29. Global Retinal Degenerative Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Retinal Degenerative Disease Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Retinal Degenerative Disease Treatment Sales Value Share by Region (2021-2026) Table 32. Global Retinal Degenerative Disease Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Retinal Degenerative Disease Treatment Sales Value Share by Region (2027-2032) Table 34. Global Retinal Degenerative Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Retinal Degenerative Disease Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Retinal Degenerative Disease Treatment Sales Value Market Share by Country (2021-2026) Table 37. Global Retinal Degenerative Disease Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Retinal Degenerative Disease Treatment Sales Value Market Share by Country (2027-2032) Table 39. Sucampo Pharmaceuticals Company Information Table 40. Sucampo Pharmaceuticals Business Overview Table 41. Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio Table 43. Sucampo Pharmaceuticals Recent Development Table 44. Vivani Medical(Second Sight Medical) Company Information Table 45. Vivani Medical(Second Sight Medical) Business Overview Table 46. Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Product Portfolio Table 48. Vivani Medical(Second Sight Medical) Recent Development Table 49. Roche Company Information Table 50. Roche Business Overview Table 51. Roche Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Roche Retinal Degenerative Disease Treatment Product Portfolio Table 53. Roche Recent Development Table 54. ReNeuron Company Information Table 55. ReNeuron Business Overview Table 56. ReNeuron Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. ReNeuron Retinal Degenerative Disease Treatment Product Portfolio Table 58. ReNeuron Recent Development Table 59. ReGenX Biosciences Company Information Table 60. ReGenX Biosciences Business Overview Table 61. ReGenX Biosciences Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. ReGenX Biosciences Retinal Degenerative Disease Treatment Product Portfolio Table 63. ReGenX Biosciences Recent Development Table 64. Regeneron Pharmaceuticals Company Information Table 65. Regeneron Pharmaceuticals Business Overview Table 66. Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio Table 68. Regeneron Pharmaceuticals Recent Development Table 69. Orphagen Pharmaceuticals, Inc. Company Information Table 70. Orphagen Pharmaceuticals, Inc. Business Overview Table 71. Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 73. Orphagen Pharmaceuticals, Inc. Recent Development Table 74. Okuvision Company Information Table 75. Okuvision Business Overview Table 76. Okuvision Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Okuvision Retinal Degenerative Disease Treatment Product Portfolio Table 78. Okuvision Recent Development Table 79. Ocugen Company Information Table 80. Ocugen Business Overview Table 81. Ocugen Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Ocugen Retinal Degenerative Disease Treatment Product Portfolio Table 83. Ocugen Recent Development Table 84. Novartis Company Information Table 85. Novartis Business Overview Table 86. Novartis Retinal Degenerative Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Novartis Retinal Degenerative Disease Treatment Product Portfolio Table 88. Novartis Recent Development Table 89. Nano Retina Company Information Table 90. Nano Retina Business Overview Table 91. Nano Retina Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Nano Retina Retinal Degenerative Disease Treatment Product Portfolio Table 93. Nano Retina Recent Development Table 94. M's Science Corporation Company Information Table 95. M's Science Corporation Business Overview Table 96. M's Science Corporation Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. M's Science Corporation Retinal Degenerative Disease Treatment Product Portfolio Table 98. M's Science Corporation Recent Development Table 99. Mimetogen Pharmaceuticals Inc. Company Information Table 100. Mimetogen Pharmaceuticals Inc. Business Overview Table 101. Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 103. Mimetogen Pharmaceuticals Inc. Recent Development Table 104. Kanghong Pharma Company Information Table 105. Kanghong Pharma Business Overview Table 106. Kanghong Pharma Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Kanghong Pharma Retinal Degenerative Disease Treatment Product Portfolio Table 108. Kanghong Pharma Recent Development Table 109. Ionis Pharmaceuticals, Inc. Company Information Table 110. Ionis Pharmaceuticals, Inc. Business Overview Table 111. Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 113. Ionis Pharmaceuticals, Inc. Recent Development Table 114. International Stem Cell Corporation Company Information Table 115. International Stem Cell Corporation Business Overview Table 116. International Stem Cell Corporation Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 117. International Stem Cell Corporation Retinal Degenerative Disease Treatment Product Portfolio Table 118. International Stem Cell Corporation Recent Development Table 119. InFlectis BioScience Company Information Table 120. InFlectis BioScience Business Overview Table 121. InFlectis BioScience Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 122. InFlectis BioScience Retinal Degenerative Disease Treatment Product Portfolio Table 123. InFlectis BioScience Recent Development Table 124. Grupo Ferrer Internacional, S.A. Company Information Table 125. Grupo Ferrer Internacional, S.A. Business Overview Table 126. Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 127. Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Product Portfolio Table 128. Grupo Ferrer Internacional, S.A. Recent Development Table 129. GenSight Biologics S.A. Company Information Table 130. GenSight Biologics S.A. Business Overview Table 131. GenSight Biologics S.A. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 132. GenSight Biologics S.A. Retinal Degenerative Disease Treatment Product Portfolio Table 133. GenSight Biologics S.A. Recent Development Table 134. Genethon Company Information Table 135. Genethon Business Overview Table 136. Genethon Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 137. Genethon Retinal Degenerative Disease Treatment Product Portfolio Table 138. Genethon Recent Development Table 139. Genable Technologies Limited Company Information Table 140. Genable Technologies Limited Business Overview Table 141. Genable Technologies Limited Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 142. Genable Technologies Limited Retinal Degenerative Disease Treatment Product Portfolio Table 143. Genable Technologies Limited Recent Development Table 144. Dompe Farmaceutici S.p.A. Company Information Table 145. Dompe Farmaceutici S.p.A. Business Overview Table 146. Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 147. Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Product Portfolio Table 148. Dompe Farmaceutici S.p.A. Recent Development Table 149. Caladrius Biosciences, Inc. Company Information Table 150. Caladrius Biosciences, Inc. Business Overview Table 151. Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 152. Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 153. Caladrius Biosciences, Inc. Recent Development Table 154. Bayer HealthCare Company Information Table 155. Bayer HealthCare Business Overview Table 156. Bayer HealthCare Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 157. Bayer HealthCare Retinal Degenerative Disease Treatment Product Portfolio Table 158. Bayer HealthCare Recent Development Table 159. Astellas Pharma Inc. Company Information Table 160. Astellas Pharma Inc. Business Overview Table 161. Astellas Pharma Inc. Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 162. Astellas Pharma Inc. Retinal Degenerative Disease Treatment Product Portfolio Table 163. Astellas Pharma Inc. Recent Development Table 164. Amarantus BioScience Company Information Table 165. Amarantus BioScience Business Overview Table 166. Amarantus BioScience Retinal Degenerative Disease Treatment Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 167. Amarantus BioScience Retinal Degenerative Disease Treatment Product Portfolio Table 168. Amarantus BioScience Recent Development Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Retinal Degenerative Disease Treatment Product Image Figure 2. Global Retinal Degenerative Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Retinal Degenerative Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Retinal Degenerative Disease Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Age Related Macular Degeneration (AMD) Treatment Image Figure 8. Retinitis Pigmentosa (RP) Treatment Image Figure 9. Global Retinal Degenerative Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Retinal Degenerative Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Retinal Degenerative Disease Treatment Sales Value Share by Type (2021-2032) Figure 12. 20 to 60 Years Old Image Figure 13. 60 and Over Image Figure 14. Others Image Figure 15. Global Retinal Degenerative Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Retinal Degenerative Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Retinal Degenerative Disease Treatment Sales Value Share by Application (2021-2032) Figure 18. Global Retinal Degenerative Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Retinal Degenerative Disease Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Retinal Degenerative Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 21. North America Retinal Degenerative Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Retinal Degenerative Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Retinal Degenerative Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Retinal Degenerative Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Retinal Degenerative Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Retinal Degenerative Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. South America Retinal Degenerative Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Retinal Degenerative Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Retinal Degenerative Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Age Related Macular Degeneration (AMD) Treatment
  • Retinitis Pigmentosa (RP) Treatment
Applications
  • 20 to 60 Years Old
  • 60 and Over
  • Others
Companies covered
  • Sucampo Pharmaceuticals
  • Vivani Medical(Second Sight Medical)
  • Roche
  • ReNeuron
  • ReGenX Biosciences
  • Regeneron Pharmaceuticals
  • Orphagen Pharmaceuticals, Inc.
  • Okuvision
  • Ocugen
  • Novartis
  • Nano Retina
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Kanghong Pharma
  • Ionis Pharmaceuticals, Inc.
  • International Stem Cell Corporation
  • InFlectis BioScience
  • Grupo Ferrer Internacional, S.A.
  • GenSight Biologics S.A.
  • Genethon
  • Genable Technologies Limited
  • Dompe Farmaceutici S.p.A.
  • Caladrius Biosciences, Inc.
  • Bayer HealthCare
  • Astellas Pharma Inc.
  • Amarantus BioScience

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Retinal Degenerative Disease Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Retinal Degenerative Disease Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Retinal Degenerative Disease Treatment Market Dynamics
  1. 2.1 Retinal Degenerative Disease Treatment Industry Trends
  2. 2.2 Retinal Degenerative Disease Treatment Industry Drivers
  3. 2.3 Retinal Degenerative Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Retinal Degenerative Disease Treatment Industry Restraints
3 Retinal Degenerative Disease Treatment Market by Company
  1. 3.1 Global Retinal Degenerative Disease Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Retinal Degenerative Disease Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Retinal Degenerative Disease Treatment Company Ranking (2024-2026)
  4. 3.4 Global Retinal Degenerative Disease Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Retinal Degenerative Disease Treatment Company Product Type and Application
  6. 3.6 Global Retinal Degenerative Disease Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Retinal Degenerative Disease Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Retinal Degenerative Disease Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Retinal Degenerative Disease Treatment Market by Type
  1. 4.1 Retinal Degenerative Disease Treatment Type Introduction
  2. 4.1.1 Age Related Macular Degeneration (AMD) Treatment
  3. 4.1.2 Retinitis Pigmentosa (RP) Treatment
  4. 4.2 Global Retinal Degenerative Disease Treatment Sales Value by Type
  5. 4.2.1 Global Retinal Degenerative Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Retinal Degenerative Disease Treatment Sales Value by Type (2021-2032)
  7. 4.2.3 Global Retinal Degenerative Disease Treatment Sales Value Share by Type (2021-2032)
5 Retinal Degenerative Disease Treatment Market by Application
  1. 5.1 Retinal Degenerative Disease Treatment Application Introduction
  2. 5.1.1 20 to 60 Years Old
  3. 5.1.2 60 and Over
  4. 5.1.3 Others
  5. 5.2 Global Retinal Degenerative Disease Treatment Sales Value by Application
  6. 5.2.1 Global Retinal Degenerative Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Retinal Degenerative Disease Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Retinal Degenerative Disease Treatment Sales Value Share by Application (2021-2032)
6 Retinal Degenerative Disease Treatment Regional Value Analysis
  1. 6.1 Global Retinal Degenerative Disease Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Retinal Degenerative Disease Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Retinal Degenerative Disease Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Retinal Degenerative Disease Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Retinal Degenerative Disease Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Retinal Degenerative Disease Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Retinal Degenerative Disease Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Retinal Degenerative Disease Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Retinal Degenerative Disease Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Retinal Degenerative Disease Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Retinal Degenerative Disease Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Retinal Degenerative Disease Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Retinal Degenerative Disease Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Retinal Degenerative Disease Treatment Sales Value Share by Country, 2025 VS 2032
7 Retinal Degenerative Disease Treatment Country-level Value Analysis
  1. 7.1 Global Retinal Degenerative Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Retinal Degenerative Disease Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Retinal Degenerative Disease Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Retinal Degenerative Disease Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Retinal Degenerative Disease Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Retinal Degenerative Disease Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Retinal Degenerative Disease Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sucampo Pharmaceuticals
  2. 8.1.1 Sucampo Pharmaceuticals Company Information
  3. 8.1.2 Sucampo Pharmaceuticals Business Overview
  4. 8.1.3 Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sucampo Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
  6. 8.1.5 Sucampo Pharmaceuticals Recent Developments
  7. 8.2 Vivani Medical(Second Sight Medical)
  8. 8.2.1 Vivani Medical(Second Sight Medical) Company Information
  9. 8.2.2 Vivani Medical(Second Sight Medical) Business Overview
  10. 8.2.3 Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Vivani Medical(Second Sight Medical) Retinal Degenerative Disease Treatment Product Portfolio
  12. 8.2.5 Vivani Medical(Second Sight Medical) Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Retinal Degenerative Disease Treatment Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 ReNeuron
  20. 8.4.1 ReNeuron Company Information
  21. 8.4.2 ReNeuron Business Overview
  22. 8.4.3 ReNeuron Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ReNeuron Retinal Degenerative Disease Treatment Product Portfolio
  24. 8.4.5 ReNeuron Recent Developments
  25. 8.5 ReGenX Biosciences
  26. 8.5.1 ReGenX Biosciences Company Information
  27. 8.5.2 ReGenX Biosciences Business Overview
  28. 8.5.3 ReGenX Biosciences Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ReGenX Biosciences Retinal Degenerative Disease Treatment Product Portfolio
  30. 8.5.5 ReGenX Biosciences Recent Developments
  31. 8.6 Regeneron Pharmaceuticals
  32. 8.6.1 Regeneron Pharmaceuticals Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals Retinal Degenerative Disease Treatment Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Recent Developments
  37. 8.7 Orphagen Pharmaceuticals, Inc.
  38. 8.7.1 Orphagen Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Orphagen Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Orphagen Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
  42. 8.7.5 Orphagen Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Okuvision
  44. 8.8.1 Okuvision Company Information
  45. 8.8.2 Okuvision Business Overview
  46. 8.8.3 Okuvision Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Okuvision Retinal Degenerative Disease Treatment Product Portfolio
  48. 8.8.5 Okuvision Recent Developments
  49. 8.9 Ocugen
  50. 8.9.1 Ocugen Company Information
  51. 8.9.2 Ocugen Business Overview
  52. 8.9.3 Ocugen Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ocugen Retinal Degenerative Disease Treatment Product Portfolio
  54. 8.9.5 Ocugen Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Retinal Degenerative Disease Treatment Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Nano Retina
  62. 8.11.1 Nano Retina Company Information
  63. 8.11.2 Nano Retina Business Overview
  64. 8.11.3 Nano Retina Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nano Retina Retinal Degenerative Disease Treatment Product Portfolio
  66. 8.11.5 Nano Retina Recent Developments
  67. 8.12 M's Science Corporation
  68. 8.12.1 M's Science Corporation Company Information
  69. 8.12.2 M's Science Corporation Business Overview
  70. 8.12.3 M's Science Corporation Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  71. 8.12.4 M's Science Corporation Retinal Degenerative Disease Treatment Product Portfolio
  72. 8.12.5 M's Science Corporation Recent Developments
  73. 8.13 Mimetogen Pharmaceuticals Inc.
  74. 8.13.1 Mimetogen Pharmaceuticals Inc. Company Information
  75. 8.13.2 Mimetogen Pharmaceuticals Inc. Business Overview
  76. 8.13.3 Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mimetogen Pharmaceuticals Inc. Retinal Degenerative Disease Treatment Product Portfolio
  78. 8.13.5 Mimetogen Pharmaceuticals Inc. Recent Developments
  79. 8.14 Kanghong Pharma
  80. 8.14.1 Kanghong Pharma Company Information
  81. 8.14.2 Kanghong Pharma Business Overview
  82. 8.14.3 Kanghong Pharma Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Kanghong Pharma Retinal Degenerative Disease Treatment Product Portfolio
  84. 8.14.5 Kanghong Pharma Recent Developments
  85. 8.15 Ionis Pharmaceuticals, Inc.
  86. 8.15.1 Ionis Pharmaceuticals, Inc. Company Information
  87. 8.15.2 Ionis Pharmaceuticals, Inc. Business Overview
  88. 8.15.3 Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Ionis Pharmaceuticals, Inc. Retinal Degenerative Disease Treatment Product Portfolio
  90. 8.15.5 Ionis Pharmaceuticals, Inc. Recent Developments
  91. 8.16 International Stem Cell Corporation
  92. 8.16.1 International Stem Cell Corporation Company Information
  93. 8.16.2 International Stem Cell Corporation Business Overview
  94. 8.16.3 International Stem Cell Corporation Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  95. 8.16.4 International Stem Cell Corporation Retinal Degenerative Disease Treatment Product Portfolio
  96. 8.16.5 International Stem Cell Corporation Recent Developments
  97. 8.17 InFlectis BioScience
  98. 8.17.1 InFlectis BioScience Company Information
  99. 8.17.2 InFlectis BioScience Business Overview
  100. 8.17.3 InFlectis BioScience Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  101. 8.17.4 InFlectis BioScience Retinal Degenerative Disease Treatment Product Portfolio
  102. 8.17.5 InFlectis BioScience Recent Developments
  103. 8.18 Grupo Ferrer Internacional, S.A.
  104. 8.18.1 Grupo Ferrer Internacional, S.A. Company Information
  105. 8.18.2 Grupo Ferrer Internacional, S.A. Business Overview
  106. 8.18.3 Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Grupo Ferrer Internacional, S.A. Retinal Degenerative Disease Treatment Product Portfolio
  108. 8.18.5 Grupo Ferrer Internacional, S.A. Recent Developments
  109. 8.19 GenSight Biologics S.A.
  110. 8.19.1 GenSight Biologics S.A. Company Information
  111. 8.19.2 GenSight Biologics S.A. Business Overview
  112. 8.19.3 GenSight Biologics S.A. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  113. 8.19.4 GenSight Biologics S.A. Retinal Degenerative Disease Treatment Product Portfolio
  114. 8.19.5 GenSight Biologics S.A. Recent Developments
  115. 8.20 Genethon
  116. 8.20.1 Genethon Company Information
  117. 8.20.2 Genethon Business Overview
  118. 8.20.3 Genethon Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Genethon Retinal Degenerative Disease Treatment Product Portfolio
  120. 8.20.5 Genethon Recent Developments
  121. 8.21 Genable Technologies Limited
  122. 8.21.1 Genable Technologies Limited Company Information
  123. 8.21.2 Genable Technologies Limited Business Overview
  124. 8.21.3 Genable Technologies Limited Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Genable Technologies Limited Retinal Degenerative Disease Treatment Product Portfolio
  126. 8.21.5 Genable Technologies Limited Recent Developments
  127. 8.22 Dompe Farmaceutici S.p.A.
  128. 8.22.1 Dompe Farmaceutici S.p.A. Company Information
  129. 8.22.2 Dompe Farmaceutici S.p.A. Business Overview
  130. 8.22.3 Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Dompe Farmaceutici S.p.A. Retinal Degenerative Disease Treatment Product Portfolio
  132. 8.22.5 Dompe Farmaceutici S.p.A. Recent Developments
  133. 8.23 Caladrius Biosciences, Inc.
  134. 8.23.1 Caladrius Biosciences, Inc. Company Information
  135. 8.23.2 Caladrius Biosciences, Inc. Business Overview
  136. 8.23.3 Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Caladrius Biosciences, Inc. Retinal Degenerative Disease Treatment Product Portfolio
  138. 8.23.5 Caladrius Biosciences, Inc. Recent Developments
  139. 8.24 Bayer HealthCare
  140. 8.24.1 Bayer HealthCare Company Information
  141. 8.24.2 Bayer HealthCare Business Overview
  142. 8.24.3 Bayer HealthCare Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Bayer HealthCare Retinal Degenerative Disease Treatment Product Portfolio
  144. 8.24.5 Bayer HealthCare Recent Developments
  145. 8.25 Astellas Pharma Inc.
  146. 8.25.1 Astellas Pharma Inc. Company Information
  147. 8.25.2 Astellas Pharma Inc. Business Overview
  148. 8.25.3 Astellas Pharma Inc. Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Astellas Pharma Inc. Retinal Degenerative Disease Treatment Product Portfolio
  150. 8.25.5 Astellas Pharma Inc. Recent Developments
  151. 8.26 Amarantus BioScience
  152. 8.26.1 Amarantus BioScience Company Information
  153. 8.26.2 Amarantus BioScience Business Overview
  154. 8.26.3 Amarantus BioScience Retinal Degenerative Disease Treatment Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Amarantus BioScience Retinal Degenerative Disease Treatment Product Portfolio
  156. 8.26.5 Amarantus BioScience Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst